Clinical Trials Logo
  1. Home
  2. Mixed Dyslipidemia
  3. NCT00171236
  4. Details
NCT00171236 Clinical Trial

Efficacy and Safety of Fluvastatin in Children With Heterozygous Familial Hypercholesterolemia

Mixed Dyslipidemia Clinical Trial

Official title:
Efficacy and Safety of Fluvastatin in Children With Heterozygous Familial Hypercholesterolemia

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00171236
Other study ID # CXUO320B2301
Secondary ID
Status Completed
Phase Phase 3
First received September 12, 2005
Last updated November 7, 2011
Start date October 2001
Est. completion date March 2005

Study information
Verified date September 2005
Source Novartis
Contact n/a
Is FDA regulated No
Health authority Netherlands: Medicines Evaluation Board (MEB)United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of the study is to assess the safety and efficacy of fluvastatin in children diagnosed with heterozygous familial hypercholesterolemia

Recruitment information / eligibility
Status Completed
Enrollment 84
Est. completion date March 2005
Est. primary completion date March 2005
Accepts healthy volunteers No
Gender Both
Age group 10 Years to 16 Years
Eligibility Inclusion Criteria:

- 10-16 years old Heterozygous familial hypercholesterolemia

Exclusion Criteria:

- Homozygous familial hypercholesterolemia Pregnant or lactating females Major surgery during the six month prior study

Other protocol defined inclusion and exclusion criteria may apply

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Drug:
• Fluvastatin

Locations
Country Name City State
Switzerland Novartis Basel

Sponsors (1)
Lead Sponsor Collaborator
Novartis

Country where clinical trial is conducted

Switzerland, 

See also
  Status Clinical Trial Phase
Completed NCT04998201 - Study of ARO-APOC3 in Adults With Mixed Dyslipidemia Phase 2
Not yet recruiting NCT03648788 - A Post-marketing Surveillance to Assess Safety and Efficacy of Rosuvatatin/Ezetimibe
Completed NCT00300430 - Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia. Phase 3
Recruiting NCT05399992 - Study Evaluating Effectiveness and Adherence of Inclisiran Plus Standard of Care (SoC) Lipid-lowering Therapy Compared to SoC in ASCVD
Withdrawn NCT05798390 - Treatment With Bempedoic Acid And/Or Its Fixed-dose Combination With Ezetimibe in Routine Clinical Practice in Patients With Primary Hypercholesterolemia Or Mixed Dyslipidemia
Completed NCT01256476 - Prevail-Us: A Study Of Pitavastatin 4 mg Vs. Pravastatin 40 mg In Patients With Primary Hyperlipidemia Or Mixed Dyslipidemia Phase 4
Completed NCT00487591 - An Evaluation of Simvastatin Plus Omacor Compared to Simvastatin Plus Placebo in Subjects With Mixed Dyslipidemia Phase 4
Terminated NCT03433755 - Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed Dyslipidemia Phase 3
Completed NCT02739984 - Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia Phase 3
Not yet recruiting NCT06386419 - A Clinical Study to Evaluate the Safety and Effectiveness of Inclisiran Sodium in Indian Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia Phase 4
Terminated NCT01335997 - Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143) Phase 3
Completed NCT00300482 - Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood Phase 3
Completed NCT00300456 - Evaluate Safety and Efficacy of ABT-335 in Combination With Simvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood Phase 3
Completed NCT00300469 - Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood Phase 3
Recruiting NCT06314919 - A Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin/Ezetimib
Terminated NCT01274559 - Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133) Phase 3
Active, not recruiting NCT04832971 - Study of ARO-ANG3 in Adults With Mixed Dyslipidemia Phase 2
Completed NCT00491530 - A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia Phase 3
Completed NCT00136799 - Efficacy and Safety of Fluvastatin in Different Doses in Adults With Mixed Dyslipidemia or Primary Hypercholesterolemia Phase 3
Completed NCT00479882 - MK-0524B Lipid Study (MK-0524B-063) Phase 3